NDA 203756 · Exelixis
Cometriq
Cabozantinib S-Malate · Oral
NovelPriority reviewOrphanLast checked: Nov 21, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Nov 29, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
45
3 Phase 3, 6 recruiting
FAERS reports
5,563
3,912 serious, 976 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 18, 2025.
COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )
Mechanism: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2016 Supplement 2 · Efficacy LabelLetter
- Nov 29, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
2 products under this application
- COMETRIQ · CABOZANTINIB S-MALATE EQ 80MG BASE · CAPSULE, ORAL · Prescription
- COMETRIQ · CABOZANTINIB S-MALATE EQ 20MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabozantinib S-Malate" as an intervention, any sponsor and status, largest first.
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaPivotal-lookingSuspended
National Cancer Institute (NCI)NIH
NCT05691478 · 1,122 participants (planned) · Start Mar 3, 2023 · Primary completion Mar 20, 2030
Drug: Cabozantinib S-malate; Cisplatin and 2 more · For: High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma and 1 more
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 202 sites in all
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05092958 · 654 participants (planned) · Start Jun 3, 2022 · Primary completion Jul 15, 2029
Drug: Avelumab; Cabozantinib S-malate · For: Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma and 15 more
Sites: Phoenix, Arizona; Auburn, California; Berkeley, California · 275 sites in all
National Cancer Institute (NCI)NIH
NCT03866382 · 314 participants (planned) · Start May 13, 2019 · Primary completion Feb 28, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 582 sites in all
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03375320 · 298 participants · Start Oct 26, 2018 · Primary completion Aug 23, 2023
Drug: Cabozantinib S-malate · For: Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm and 25 more
Sites: Anchorage, Alaska; Kingman, Arizona; Phoenix, Arizona · 432 sites in all
- Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05411081 · 200 participants (planned) · Start Mar 24, 2023 · Primary completion Jul 1, 2027
Drug: Atezolizumab; Cabozantinib S-malate · For: Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Sites: Gilbert, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 198 sites in all
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01835158 · 157 participants · Start Jul 8, 2013 · Primary completion Apr 18, 2016
Drug: Cabozantinib S-malate; Sunitinib Malate · For: Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7 and 1 more
Sites: Mobile, Alabama; Anchorage, Alaska; Burbank, California · 488 sites in all
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02496208 · 152 participants (planned) · Start Jul 22, 2015 · Primary completion Jul 30, 2027
Drug: Cabozantinib S-malate; Ipilimumab and 1 more · For: Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urothelial Carcinoma and 27 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 8 sites in all
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02761057 · 152 participants · Start Jul 25, 2016 · Primary completion Oct 19, 2023
Drug: Cabozantinib S-malate; Crizotinib and 2 more · For: Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7 and 4 more
Sites: Anchorage, Alaska; Kingman, Arizona; Fort Smith, Arkansas · 595 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,109
- diarrhoea1,034
- fatigue713
- nausea516
- malignant neoplasm progression477
- decreased appetite452
- asthenia333
- stomatitis332
- weight decreased329
- death317
- vomiting301
- palmar-plantar erythrodysaesthesia syndrome268
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 214 |
| 2014 | 304 |
| 2015 | 304 |
| 2016 | 147 |
| 2017 | 518 |
| 2018 | 626 |
| 2019 | 505 |
| 2020 | 419 |
| 2021 | 605 |
| 2022 | 637 |
| 2023 | 502 |
| 2024 | 288 |
| 2025 | 285 |
| 2026 | 206 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cometriq (Cabozantinib S-Malate)
2024 spending
$3.3M
Beneficiaries
41
202 claims
Per beneficiary
$81,546
$244.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,076,795 |
| 2021 | $5,847,707 |
| 2022 | $3,978,052 |
| 2023 | $3,456,787 |
| 2024 | $3,343,405 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P, Carroll C, Hamilton J, et al. · Health Technol Assess 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Nguyen L, Benrimoh N, Xie Y, et al. · Anticancer Drugs 2016 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Exelixis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.